Gilead fires back in on­go­ing bat­tle with HHS, su­ing the gov­ern­ment for ‘se­cret­ly’ ob­tain­ing patents

3 years ago
R&D

An on­col­o­gy up­start with some deep-pock­et VC con­nec­tions has a uni­corn-sized ven­ture round to back the pipeline

3 years ago
Financing
Startups

Covid-19 roundup: Sanofi & Re­gen­eron de­liv­er dis­ap­point­ing news on IL-6; Alex Azar ru­mors are swirling at HHS

3 years ago
R&D
Coronavirus

#AACR20: Io­vance rev­els in promis­ing lung can­cer da­ta out of Mof­fitt as TIL ther­a­py trig­gers 2 com­plete re­spons­es

3 years ago
R&D

Eli Lil­ly ex­ecs have been think­ing about the longterm ef­fects of the pan­dem­ic and dam­age con­trol. Here’s what they be­lieve

3 years ago
People
R&D

Covid-19 roundup: Sanofi promis­es to bring re­com­bi­nant vac­cine ca­pac­i­ty to 1B+ while scal­ing up mR­NA man­u­fac­tur­ing

3 years ago
Coronavirus

Sanofi steps up with its da­ta on a new MS drug, shin­ing a spot­light on PhI­II hopes af­ter fend­ing off a short at­tack

3 years ago
R&D

Ven­rock joins the biotech VC fundrais­ing game, toss­ing $447M in­to a $4.3B pot of new mon­ey

3 years ago
Financing

‘Break­through’ drugs in­clud­ed on Roche’s list of PhII/III stud­ies axed in Q1 — with piv­otal Mir­ros tri­al on the chop­ping block

3 years ago
R&D

Bio­gen push­es back its time­line on the big ad­u­canum­ab FDA fil­ing as Covid-19 slows work — shares wilt

3 years ago
R&D

VA study spot­lights high­er death rate among Covid-19 pa­tients treat­ed with the con­tro­ver­sial drug hy­drox­y­chloro­quine

3 years ago
R&D
Coronavirus

Astel­las snaps up mi­to­chon­dria-fo­cused biotech, beefs up drug dis­cov­ery in bud­get deal

3 years ago
Deals

Short at­tack tar­gets one of the fa­vorites now shar­ing the lead in the pop­u­lar KRAS drug de­vel­op­ment race

3 years ago
R&D

Data­vant boots up a big Covid-19 reg­istry — look­ing to shine a light on virus spread, im­pact and most ef­fec­tive ther­a­pies

3 years ago
R&D
Coronavirus

Ex­elix­is lands PhI­II kid­ney can­cer win with Bris­tol My­ers in their hunt for $4 bil­lion

3 years ago
R&D

It’s not the mon­ey: The lat­est For­tune list of the top 10 bio­phar­mas to work for in­cludes a few sur­prise play­ers

3 years ago
People

Covid-19 roundup: HHS of­fi­cial Giroir takes on role of test­ing czar — cue new con­tro­ver­sy; Wuhan lab ve­he­ment­ly de­nies trig­ger­ing the pan­dem­ic

3 years ago
Coronavirus

With third FDA ap­proval, Seat­tle Ge­net­ics plans vir­tu­al launch of metasta­t­ic breast can­cer drug amid coro­n­avirus pan­dem­ic

3 years ago
Pharma
FDA+

Re­port on one PhI­II remde­sivir study sends in­vestors in­to over­drive, adding bil­lions to Gilead­'s mar­ket cap

3 years ago
R&D
Coronavirus

Covid-19 roundup: Trump changes tune with plan to lift re­stric­tions; FDA in­di­cates its non-coro­n­avirus pace may take a hit

3 years ago
Coronavirus

BAR­DA bets $483M on Mod­er­na’s Covid-19 vac­cine as the biotech plots ul­tra-fast PhI­II, re­cruit­ing 150 staffers to scale up 24/7

3 years ago
Deals
Coronavirus

Har­vard profs main­tain that the FDA's re­cent ac­tions on Covid-19 de­val­ue the gold stan­dard and threat­en pub­lic trust

3 years ago
FDA+
Coronavirus

Covid-19 roundup: Blis­tered by heat­ed re­ac­tion to their role in the out­break, Bio­gen makes amends with Covid-19 'biobank’

3 years ago
Coronavirus

Is Gilead chief Dan O’Day ready for a new biotech deal in the on­col­o­gy field?

3 years ago
Deals
First page Previous page 112113114115116117118 Next page Last page